CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
Melphalandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02097134
NCT02097134Phase 1Completed

A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma

Children's Oncology Group·interventional·Posted Mar 26, 2014·Updated Oct 13, 2023

In Brief

A Phase 1 clinical trial evaluating Melphalan for Unilateral Retinoblastoma. Completed, enrolled 14 participants across 12 sites.

Detailed Summary

This pilot clinical trial studies whether unilateral group D retinoblastoma, or retinoblastoma affecting one eye that has spread to the inner jelly like part of the eye, can be treated with a new technique for delivering chemotherapy directly into the blood vessel that supplies the affected eye. This new technique is called intra-arterial injection. Giving melphalan via intra-arterial injection may make it less likely that children will need surgery to remove the eye and may reduce the amount of treatment side effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 26, 2014
Enrollment StartOct 31, 2014
Primary CompletionJun 30, 2017
Study CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.3 years ago

Interventions

Melphalandrug

Given IA